Centrosomes, centrioles and cell division: new targets in experimental breast cancer treatment

Written by Louis Gautier, Future Science Group

TRIM37

Collaborative research from Johns Hopkins Medicine (MD, USA) and the University of Oxford (UK) has discovered a novel method of selectively targeting human breast cancer cells by disrupting the activity and function of centrioles in cell division. The team hope to produce a stable drug inhibitor of the TRIM37 protein that controls this mechanism. The technique, so far tested only in lab-grown and patient-derived cancer cells, exploits cancers with a high level of TRIM37 expression to target two parts of centriolar function in cell division. Centriole function is key for the anaphase of cell division and selective inhibition of the...

To view the full article, please register now for access

It's completely free